% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Jun 17, 2013 8:59 AM Flag

    JNJ acquires phase II co for $650MM

    Another signal that IMGN is highly undervalued, Aragon acquired for $650MM based on a drug in phase II for PC and earlier development for BC. IMGN's business execs fails to deliver full market value for IMGN shareholders. If this continues for much longer, the solutions are an acquisition, or removal and replacement of said failing execs.

2.080.00(0.00%)Oct 26 4:00 PMEDT